
Opinion|Videos|January 13, 2025
Proactive CRS Management: The Role of Tocilizumab and Beyond
Author(s)Amrita Krishnan, MD
Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Data from ASH 2024 suggest intravenous immunoglobulin (IVIG) can play a critical role in preventing infections in patients receiving teclistamab. How do you incorporate IVIG into your clinical practice, and what considerations guide its use?
- Beyond IVIG, what additional strategies or prophylactic measures have you incorporated into your practice to reduce infection risk in patients on bispecific antibody therapies in multiple myeloma?
- Cytokine release syndrome (CRS) remains a common concern with bispecific antibodies. What strategies do you find most effective for managing CRS?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
5 Consequences If ACA Premium Subsidies End in 2026
2
Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer
3
Team-Based Precision Oncology: Advancing Value and Access in Cancer Care
4
Navigating Costs and Logistics of Cellular Therapies, ADCs, and Novel Diagnostics in Cancer Care
5
















































